Nature communications · 2026
GWAS of extended prescription analgesic use identifies genetic loci in chronic pain.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Harlow Charli E, Uzochukwu Emeka, Fernando Hazel A, Mordaunt Charles E, Hughey Jordan M, Eicher John D, Robinson Lara, Bowker Nicholas, Howe Laurence, Liu Jimmy, Cortes Adrian, Wilson Paul, Gungabissoon Usha, Benson Victoria S, Nash Anthony, Young Gareth, Addis Laura, Xu Chun-Fang, Webber Caleb, Davitte Jonathan, Cader M Zameel
Аннотация
Pain-related conditions are the leading cause of disability worldwide. Existing GWAS for chronic pain have mainly focused on individual pain-related disorders, which may not optimally capture the phenotype. Here, we define chronic pain based on prescription analgesic use ( ≥ 90 days) in two large biobanks (UK Biobank and FinnGen). GWAS meta-analyses of 11 prescription-based pain phenotypes identify 140 associations with chronic pain, including 78 novel (e.g. ARPP21, CNTNAP2) and 62 previously reported (e.g. SLC39A8, DCC, TRPM8) associations. Integrating these genetic associations with functional data including transcriptome-wide association studies, cell-type and pathway enrichment, and gene enrichment in mouse phenotypes identifies potential mechanisms involved in chronic pain, implicating oligodendrocyte differentiation, neuronal guidance, endolysosomal function and post-synaptic endosome recycling. Our study showcases how the use of prescription data to identify and characterize pain can provide insights into pain genetics and its underlying biology.